Page 12 of 24
PH1.7-9 | PH1.7-9 | Pharmacodynamics, Prototype Drug Effects and Rational Combinations — SDL Guide — SDL Guide (Part 2)
Non-Receptor Mechanisms: Enzymes, Ion Channels, and Physical Effects
Not all drugs act through classical membrane receptors. A substantial and clinically important group of drugs produce their effects by inhibiting enzymes, blocking ion channels, inhibiting membrane transporters, or acting through physicochemical mechanisms that do not require specific protein binding.
Enzyme inhibition is the mechanism of several critical drug classes. ACE inhibitors (e.g., enalapril, lisinopril) inhibit angiotensin-converting enzyme, preventing the conversion of angiotensin I to angiotensin II, thereby reducing vasoconstriction, aldosterone secretion, and ultimately blood pressure and cardiac afterload. The inhibition is competitive and reversible. Aspirin provides the canonical example of irreversible enzyme inhibition: aspirin acetylates a serine residue in the active site of both COX-1 and COX-2, permanently inactivating the enzyme. Since platelets lack nuclei (and therefore cannot synthesise new COX protein), aspirin's antiplatelet effect lasts for the platelet's entire lifespan (~7–10 days). This is mechanistically distinct from ibuprofen, which inhibits COX reversibly — platelet function returns within hours of ibuprofen clearance. HMG-CoA reductase inhibitors (statins) competitively inhibit the rate-limiting enzyme of hepatic cholesterol synthesis, a mechanism-first approach to reducing LDL.
Ion channel modulation underlies the action of another major drug class. Local anaesthetics (lidocaine, bupivacaine) block voltage-gated Na+ channels in the open or inactivated state, preventing the Na+ influx necessary for action potential generation and propagation — nerve conduction is blocked. The block is use-dependent (greater block in rapidly firing neurons) and reversible. Calcium channel blockers (CCBs) block L-type voltage-gated Ca2+ channels in cardiac and vascular smooth muscle: dihydropyridines (nifedipine, amlodipine) preferentially block vascular smooth muscle Ca2+ channels, producing vasodilation; non-dihydropyridines (verapamil, diltiazem) also block cardiac Ca2+ channels, slowing heart rate and AV conduction.
Transporter inhibition is the mechanism of SSRIs (selective serotonin reuptake inhibitors — block the SERT transporter, increasing synaptic serotonin), SNRIs, tricyclic antidepressants (block both SERT and NET), and metformin (inhibits hepatic mitochondrial complex I, reducing gluconeogenesis — though its primary target is debated; not a receptor agonist/antagonist in the classical sense).
Physicochemical mechanisms include antacids (neutralise gastric HCl — a pure acid-base chemical reaction, not receptor mediated), activated charcoal (adsorbs toxins in the GI tract), and osmotic diuretics (mannitol — increases tubular osmolality, drawing water from cells and reducing intracranial pressure, without acting on any specific protein receptor).
Prototype Drug Effects: Demonstrating PD Principles via Key Drug Classes
Prototype drugs are canonical examples — drugs whose mechanism of action, physiological effects, and clinical uses are so well characterised that they serve as the reference standard for understanding an entire drug class or pharmacodynamic principle. Learning prototype drugs deeply is more valuable than memorising the properties of every drug in a class, because the prototype predicts the class.
The following five prototypes illustrate the main pharmacodynamic mechanisms encountered in clinical practice. Each maps a mechanism onto predictable physiological effects, which in turn predict clinical uses and adverse effects:
Morphine — prototype full mu-opioid receptor agonist. Activates inhibitory Gi-coupled mu receptors in the CNS and peripheral sensory neurons. Physiological effects: analgesia (↓ pain perception and affective response), sedation, euphoria, respiratory depression (↓ CO2 sensitivity in brainstem respiratory centres), miosis (pupillary constriction via Edinger-Westphal nucleus), decreased GI motility (↓ peristalsis via enteric plexus mu receptors — the basis of constipation and the clinical use of loperamide for diarrhoea). Clinical uses: moderate-to-severe pain, acute pulmonary oedema (reduces preload perception and anxiety). Adverse effects: respiratory depression, constipation, nausea/vomiting (area postrema CTZ mu receptors), physical dependence.
Atropine — prototype competitive reversible muscarinic (M1–M5) antagonist. Blocks acetylcholine at all muscarinic receptors, producing effects opposite to parasympathetic stimulation. Physiological effects: ↑ heart rate (blocks M2 on SA node), bronchodilation (blocks M3 in airways), reduced secretions (salivary, lacrimal, bronchial, gastric), urinary retention (blocks detrusor M3), mydriasis (blocks pupillary sphincter M3), reduced GI motility. Clinical uses: bradycardia, organophosphate poisoning (reverses excessive cholinergic stimulation), pre-operative antisecretory agent, dilated eye examination. Adverse effects: dry mouth, urinary retention, constipation, tachycardia, confusion (central antimuscarinic effect in elderly).
Aspirin — prototype irreversible COX-1 and COX-2 inhibitor. By irreversibly acetylating the COX active site, aspirin prevents prostaglandin and thromboxane synthesis. Physiological effects: antiplatelet (↓ TXA2 — 7–10 day duration), anti-inflammatory (↓ PGE2 and PGI2 at inflammation site), antipyretic (↓ PGE2 in hypothalamus), analgesic (↓ peripheral sensitisation by prostaglandins). Clinical uses: antiplatelet (ACS, stroke prevention), anti-inflammatory (Kawasaki disease, rheumatic fever), analgesic/antipyretic (low dose). Adverse effects: GI irritation/ulceration (↓ PGE2 protective mucus), antiplatelet bleeding risk, salicylism in overdose.
Adrenaline (epinephrine) — prototype mixed alpha and beta adrenergic receptor agonist. Activates alpha-1 (vasoconstriction), alpha-2 (presynaptic inhibition), beta-1 (↑ heart rate and contractility), and beta-2 (bronchodilation, vasodilation in muscle) receptors. Clinical uses: anaphylaxis (alpha-1 vasoconstriction reverses hypotension; beta-2 reverses bronchospasm; beta-1 supports cardiac output), cardiac arrest (alpha-1 increases coronary perfusion pressure), added to local anaesthetics (alpha-1 vasoconstriction delays absorption and prolongs anaesthesia). Adverse effects: hypertension, arrhythmias, tissue necrosis if extravasated from IV line.
Propranolol — prototype non-selective competitive beta-1 and beta-2 adrenergic receptor antagonist. Blocks both beta-1 (↓ heart rate and contractility) and beta-2 (↑ airway resistance, ↑ peripheral vascular resistance). Clinical uses: hypertension, angina, tachyarrhythmias, thyrotoxicosis, essential tremor, migraine prophylaxis. Absolute contraindication in asthma/COPD (beta-2 blockade causes dangerous bronchoconstriction) — motivating the development of beta-1 selective antagonists.
| Prototype drug | Mechanism | Key effects | Primary clinical use |
|---|---|---|---|
| Morphine | Full mu-opioid agonist (Gi-coupled) | Analgesia, respiratory depression, miosis, constipation | Moderate-to-severe pain, acute pulmonary oedema |
| Atropine | Competitive muscarinic antagonist | Tachycardia, bronchodilation, dry secretions, mydriasis, urinary retention | Bradycardia, organophosphate poisoning |
| Aspirin | Irreversible COX-1/2 inhibitor | Antiplatelet (7–10d), anti-inflammatory, antipyretic, analgesic | Antiplatelet therapy, inflammation, fever/pain |
| Adrenaline | Mixed alpha + beta agonist | Vasoconstriction (alpha-1), ↑HR/contractility (beta-1), bronchodilation (beta-2) | Anaphylaxis, cardiac arrest |
| Propranolol | Non-selective beta antagonist | ↓HR, ↓contractility, bronchoconstriction | Hypertension, angina, arrhythmias |
SELF-CHECK
A patient with hypertension and asthma requires a beta-blocker for rate control after an acute MI. Which choice and reasoning is correct?
A. Propranolol — the most potent beta-blocker, so it provides the best cardiac protection.
B. Metoprolol — a beta-1 selective antagonist; at therapeutic doses it preferentially blocks cardiac beta-1 receptors with minimal beta-2 bronchospasm risk compared to non-selective propranolol.
C. Avoid all beta-blockers in asthma — selectivity is irrelevant because all beta-blockers cause bronchoconstriction equally.
D. Propranolol — beta-2 blockade in the lungs is beneficial in asthma by reducing airway inflammation.
Reveal Answer
Answer: B. Metoprolol — a beta-1 selective antagonist; at therapeutic doses it preferentially blocks cardiac beta-1 receptors with minimal beta-2 bronchospasm risk compared to non-selective propranolol.
Beta-1 selective antagonists (metoprolol, atenolol, bisoprolol) preferentially block beta-1 adrenergic receptors in the heart at therapeutic doses, with substantially less beta-2 blockade in the airways than non-selective beta-blockers like propranolol. In a post-MI patient with asthma, the mortality benefit of beta-blockade is well-established, and cardioselective agents can be used with caution and monitoring — they are not absolutely contraindicated as propranolol would be. Selectivity is pharmacodynamically meaningful but not absolute — it diminishes at high doses.
Rational Drug Combinations: Synergism, Antagonism, and PK-PD Rationale
Drug combinations are prescribed in the majority of patients with chronic diseases — a hypertensive patient commonly takes 2–3 antihypertensives; a patient with TB takes 4 drugs simultaneously; a patient with heart failure takes an ACE inhibitor, a beta-blocker, a diuretic, and an aldosterone antagonist. Whether a combination is rational depends on understanding the pharmacodynamic and pharmacokinetic interactions between the drugs, and whether the net effect serves the therapeutic goal better than either drug alone.
When two drugs are combined, the outcome falls into one of three categories based on their pharmacodynamic interaction:
Synergism means the combined effect is greater than or equal to the sum of the individual effects. Additive synergism occurs when effect = A + B (two drugs at their respective doses produce effects that add up linearly). Supra-additive synergism (potentiation) occurs when effect > A + B — the combination produces an effect greater than the algebraic sum. The clinical archetype of dangerous potentiation: alcohol plus benzodiazepines — both enhance GABA-A Cl− conductance, and the combination produces CNS and respiratory depression far exceeding what either produces alone. The therapeutic archetype: co-trimoxazole (trimethoprim + sulfamethoxazole) — trimethoprim inhibits dihydrofolate reductase and sulfamethoxazole inhibits dihydropteroate synthase, two sequential steps in bacterial folate synthesis; the sequential block produces a supra-additive antibacterial effect with reduced risk of resistance compared to either alone.
Antagonism means the combined effect is less than the effect of the more active drug alone. Three mechanistically distinct types:
- Pharmacological antagonism: two drugs act at the same receptor or pathway with opposing effects. Naloxone antagonises morphine at the mu receptor; neostigmine antagonises competitive neuromuscular blocking agents (tubocurarine) by increasing ACh at the NMJ.
- Chemical antagonism: the drugs react chemically to neutralise each other. Protamine sulfate neutralises heparin by ionic charge interaction; dimercaprol chelates heavy metal ions (lead, arsenic, mercury), rendering them non-toxic.
- Physiological antagonism: two drugs produce opposing effects via entirely different receptor systems. Adrenaline counters the effects of histamine in anaphylaxis — not by blocking histamine receptors, but by activating alpha and beta receptors to reverse vasodilation, bronchoconstriction, and hypotension through the adrenergic system.
Indifference (no interaction) occurs when the combined effect equals the effect of the more active agent alone — adding drug B simply adds nothing to drug A's effect.
The PK-PD rationale for rational combination therapy rests on four principles: (1) complementary mechanisms targeting different steps in the same pathophysiological pathway (as in antihypertensive combinations — ACE inhibitor + diuretic + calcium channel blocker); (2) sequential metabolic block (co-trimoxazole); (3) protection from resistance (multi-drug TB therapy); (4) allowing dose reduction of each component to minimise adverse effects while maintaining combined efficacy. Irrational combinations use drugs with the same mechanism (additive toxicity without additive benefit), oppose each other pharmacologically (ACE inhibitor + ARB in most patients — dual RAAS blockade doubles adverse effects with minimal added benefit), or create dangerous pharmacokinetic interactions.
| Combination type | Definition | Mechanism example | Clinical example | Rational or hazardous |
|---|---|---|---|---|
| Additive synergism | Effect = A + B | Two ACE inhibitors (no benefit beyond one) | Aspirin + paracetamol for pain | Rational if doses lower than monotherapy |
| Potentiation | Effect > A + B | Alcohol + benzodiazepine (GABA-A enhancement) | Trimethoprim + sulfamethoxazole | Rational (co-trimoxazole); hazardous (alcohol + BZD) |
| Pharmacological antagonism | Drug B reverses drug A at same receptor | Naloxone + morphine (mu receptor) | Neostigmine reversing neuromuscular block | Therapeutic reversal |
| Chemical antagonism | Drugs neutralise each other chemically | Protamine + heparin (ionic) | Dimercaprol + lead (chelation) | Therapeutic antidote |
| Physiological antagonism | Opposite effects, different receptors | Adrenaline + histamine (different receptors) | Adrenaline in anaphylaxis | Therapeutic |
| Indifference | No interaction | No shared pathway | Two drugs for unrelated conditions | Neutral — each acts independently |
CLINICAL PEARL
The irreversibility trap with aspirin: Patients scheduled for elective surgery are commonly told to 'stop their aspirin 7–10 days before the procedure' — a recommendation that confuses many students who know aspirin's plasma half-life is only 15–20 minutes. The confusion dissolves with pharmacodynamics: aspirin irreversibly inactivates platelet COX-1, and the 7–10 day washout period reflects the lifespan of a platelet, not aspirin's plasma t½. New platelets with intact COX-1 must be generated for normal haemostasis to return. This is the archetypal clinical example of why mechanism — not just PK half-life — determines the duration of drug effect.
SELF-CHECK
A patient takes both morphine (opioid agonist) and naloxone (opioid antagonist). Which combination outcome does this represent, and what is the mechanism?
A. Chemical antagonism — naloxone reacts with morphine to form an inactive compound.
B. Physiological antagonism — naloxone activates a different receptor that counteracts opioid effects.
C. Pharmacological antagonism — naloxone competitively occupies the mu-opioid receptor, preventing morphine binding and reversing its effects.
D. Potentiation — naloxone enhances opioid analgesia by partial agonism at the mu receptor.
Reveal Answer
Answer: C. Pharmacological antagonism — naloxone competitively occupies the mu-opioid receptor, preventing morphine binding and reversing its effects.
Naloxone is a competitive reversible antagonist at the mu-opioid receptor — it binds the same site as morphine with higher affinity but produces no agonist effect. This is pharmacological antagonism at the receptor level (same receptor, opposing outcome). It is not chemical antagonism (no chemical reaction between the molecules) and not physiological antagonism (not a different receptor system). The effect is dose-dependent and reversible — sufficient morphine concentration can overcome naloxone blockade.